Get the Stockscreener App
0.9455
2.37%
0.0219
Opus Genetics Inc stock is traded at $0.9455, with a volume of 48,001.
It is up +2.37% in the last 24 hours and down -7.30% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
See More
Previous Close:
$0.9236
Open:
$0.94
24h Volume:
48,001
Relative Volume:
0.05
Market Cap:
$60.85M
Revenue:
$8.38M
Net Income/Loss:
$-27.19M
P/E Ratio:
-0.8674
EPS:
-1.09
Net Cash Flow:
$-13.59M
1W Performance:
-4.58%
1M Performance:
-7.30%
6M Performance:
+13.92%
1Y Performance:
+0.00%
1-Day Range:
$0.9102
$0.959
1-Week Range:
$0.9102
$1.00
52-Week Range:
$0.65
$1.75
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
8 DAVIS DRIVE, DURHAM
Compare IRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
0.9455 | 60.85M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.69 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
516.92 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.99 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.29 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-11-25 | Initiated | Craig Hallum | Buy |
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
Opus Genetics Inc Stock (IRD) Latest News
Opus Genetics (IRD) Receives "Buy" Rating from Lucid Capital Mar - GuruFocus
Opus Genetics (IRD) Receives Buy Rating Amid Promising Trial Res - GuruFocus
Opus Genetics, Inc.Common Stock (Nasdaq:IRD) Stock Quote - FinancialContent
Opus Genetics (IRD) Achieves Success in Phase 3 Trial for Night Driving Vision Treatment | IRD Stock News - GuruFocus
Opus Genetics reports success in night vision trial - Investing.com
Opus Genetics reports success in night vision trial By Investing.com - Investing.com UK
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its - GlobeNewswire
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions - GlobeNewswire Inc.
Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results - simplywall.st
Opus Genetics, Inc. (NASDAQ:IRD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates - MSN
Opus Genetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Opus Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update - GlobeNewswire
IRD Reports Strong Q1 Revenue Growth and Encouraging Trial Data - GuruFocus
Opus Genetics Inc (IRD) Q1 2025 Earnings: EPS of $(0.24) Beats E - GuruFocus
IRD Reports Strong Q1 Revenue Growth and Encouraging Trial Data | IRD Stock News - GuruFocus
Opus Genetics Q1 2025 Financial Results and Corporate Update - TradingView
Opus Gene Therapy Shows 12-Month Vision Restoration Success, Gains FDA RMAT Status | IRD Stock News - Stock Titan
Opus Genetics (IRD) Showcases Advances in Gene Therapy at May Co - GuruFocus
Opus Genetics (IRD) Showcases Advances in Gene Therapy at May Conferences | IRD Stock News - GuruFocus
Opus Genetics to Present Advances in Gene Therapy for Inherited Retinal Diseases at Major Scientific Conferences in May 2025 - Nasdaq
Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May - GlobeNewswire
FDA grants RMAT status to Opus Genetics’ OPGx-LCA5 gene therapy - Yahoo Finance
Opus Genetics (IRD) Secures RMAT Status for Gene Therapy OPGx-LC - GuruFocus
Opus Genetics (IRD) Secures RMAT Status for Gene Therapy OPGx-LCA5 | IRD Stock News - GuruFocus
FDA grants Opus Genetics RMAT status for eye therapy - Investing.com
Opus Genetics Granted FDA Regenerative Medicine Advanced - GlobeNewswire
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate - The Manila Times
FDA grants Opus Genetics RMAT status for eye therapy By Investing.com - Investing.com South Africa
FDA Fast-Tracks Revolutionary Gene Therapy for Ultra-Rare Inherited Blindness Treatment - Stock Titan
Opus Genetics (IRD) Reveals Promising Gene Therapy Trial Results | IRD Stock News - GuruFocus
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision - The Manila Times
Opus Genetics Announces Presentation of OPGX-LCA5 Gene - GlobeNewswire
Gene Therapy Breakthrough: Opus Reports 3.5-Line Vision Improvement After 1 Year in Rare Eye Disease Trial - Stock Titan
IRDOpus Genetics Latest Stock News & Market Updates - Stock Titan
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline - Yahoo Finance
Opus Genetics shareholders approve key proposals By Investing.com - Investing.com Nigeria
Opus Genetics shareholders approve key proposals - Investing.com
Ocuphire Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 - marketscreener.com
PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath - markets.businessinsider.com
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opus Genetics Inc Stock (IRD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| YERXA BENJAMIN R | President |
Nov 21 '24 |
Buy |
0.98 |
10,000 |
9,834 |
342,800 |
| Magrath George | Chief Executive Officer |
Nov 15 '24 |
Buy |
1.01 |
90,294 |
91,215 |
483,244 |
| Magrath George | Chief Executive Officer |
Nov 18 '24 |
Buy |
1.02 |
9,706 |
9,943 |
492,950 |
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):